Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CS01
- Development stage
- Phase 2
- Lead developer
- Zhongshan Hengdong Biopharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CS01 is a novel, next-generation agonistic monoclonal antibody targeting OX40 (CD134), a co-stimulatory receptor belonging to the tumor necrosis factor receptor superfamily (TNFRSF) that is expressed on activated CD4+ and CD8+ T cells. CS01 is engineered with an intermediate binding-affinity Fab region and a constant domain optimized for enhanced Fcγ receptor (FcγR) engagement. This specific design is intended to facilitate superior OX40 clustering and downstream signaling, which promotes T-cell proliferation and survival within the tumor microenvironment. By enhancing the effector function of T cells, CS01 aims to bolster anti-tumor immune responses in patients with advanced malignancies. It is currently being evaluated in investigator-initiated Phase 1/2 clinical trials for the treatment of locally advanced or metastatic solid tumors.
- Other names
- agonistic anti-OX40 IgG monoclonal antibody
Beyond the preview
Go deeper on CS01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CS01.